PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of nihpaAbout Author manuscriptsSubmit a manuscriptNIH Public Access; Author Manuscript; Accepted for publication in peer reviewed journal;
 
J Immunol Methods. Author manuscript; available in PMC Oct 31, 2011.
Published in final edited form as:
PMCID: PMC2964415
NIHMSID: NIHMS235095
A flow cytometry based assay to assess RSV specific neutralizing antibody is reproducible, efficient and accurate
M Chen,1 JS Chang,2 M Nason,3 D Rangel,4 JG Gall,4 BS Graham,1 and JE Ledgerwood1*
1Viral Pathogenesis Laboratory and Clinical Trials Core, Vaccine Research Center, National Institutes of Allergy and Infectious Diseases, National Institutes of Health, US Department of Health and Human Services, 40 Convent Drive, Bethesda, Maryland 20892
2Department of Renal Care, College of Medicine, Kaohsiung Medical University, 100 Shih-Chuan 1st Road, Kaohsiung 807, Taiwan
3Biostatistics Research Branch, Division of Clinical Research, National Institutes of Allergy and Infectious Diseases, National Institutes of Health, US Department of Health and Human Services, Bethesda, Maryland 20892
4GenVec, Inc., 65 West Watkins Mill Rd., Gaithersburg, Maryland 20878
*Corresponding Author Julie E. Ledgerwood, D.O., Tel: 301-594-8502, Ledgerwood/at/mail.nih.gov
Respiratory syncytial virus (RSV) is an important cause of respiratory infection in people of all ages, and is the leading cause of hospitalization in infants. Although commercially available monoclonal antibody is available for passive prophylaxis of neonates at risk of severe disease, there is no available vaccine to prevent RSV. Measurement of neutralizing activity will be a key endpoint for vaccine evaluation. Assessment of neutralizing antibody against RSV has been limited to traditional plaque reduction, which is time consuming and inherently operator dependent and highly variable. Here, we describe a flow cytometry-based RSV-specific neutralization assay which is more rapid than traditional methods, highly sensitive and highly reproducible.
Respiratory syncytial virus (RSV) is a pneumovirus in the family Paramyxoviridae, which also includes metapneumovirus. RSV is a major cause of infant respiratory infection, especially severe pneumonia and bronchiolitis (Glezen et al., 1981; Collins and Graham, 2008). There are three envelope proteins F, G, and SH. Both F and G are glycosylated and represent the targets of neutralizing antibodies. F-specific neutralizing antibody is known to be protective, and there is a licensed monoclonal antibody, Synagis® (Palivizumab) that is used to passively protect high risk infants from severe disease (Johnson et al., 1997). Assessment of neutralizing activity in preclinical or clinical samples has been primarily by traditional plaque reduction neutralization (PRNT) or microneutralization (Anderson et al., 1985). PRNT suffers from limited sensitivity and nonspecificity, and is prone to technician error, is tedious, labor-intensive, and is not as reproducible as newer reporter pseudovirus methods developed for other viral diseases (Mascola et al., 2002; Pierson et al., 2006; Martin et al., 2008). Additionally the PRNT assay is time-consuming and not easily adapted to high throughput technology. Here we describe an efficient, highly reproducible flow cytometry-based assay to detect RSV neutralization with high sensitivity and specificity.
Virus
Viral stocks of RSV expressing Green Fluorescent Protein (GFP) and based on the A2 strain of RSV, were prepared and maintained as previously described (Graham et al., 1988). GFP-RSV was constructed and provided by Mark Peeples and Peter Collins, as previously reported (Hallak et al., 2000). The titer of the virus stocks used for the experiments was 2.5×107 pfu/ml.
Cell line
HEp-2 cells were maintained in Eagle's minimal essential medium containing 10% fetal bovine serum (10% EMEM) and were supplemented with 2 mM glutamine, 10 U of penicillin G per ml, and 10 µg of streptomycin sulfate per ml.
Antibody controls
Anti-RSV monoclonal antibody, Synagis® (palivizumab) was purchased from Medimmune, LLC (Gaithersburg, MD).Human plasma was obtained from healthy adult donors at the Vaccine Research Center clinic through an NIAID IRB approved study for blood donation at the NIH. Convalescent mouse and rabbit sera were obtained from the Viral Pathogenesis Laboratory, VRC, NIAID.
Flow cytometry neutralization assay
Antibody-mediated neutralization was measured as a function of GFP-expressing RSV infection using HEp-2 cells. GFP-RSV was added to serial four-fold dilutions (beginning with a dilution of 1:10) of (serum or antibody) in 96-well plates, which were seeded with HEp-2 cells at 5×104/100 mcl per well, and incubated at 37°C for one hour. Serum concentrations ranged from 1:10 to 1:40,960. After one hour, 100 µl of the virus/serum mixture was added to each of the wells in 96-well plates (5×104 cells/well). Infection was monitored as a function of GFP expression (encoded by the viral genome) at 18 hours post-infection by flow cytometry (LSR II, BD Bioscience, CA, USA). Prior to assessment by flow cytometry, cells were treated with trypsin to ensure a single-cell suspension optimal for analysis and fixed with 0.5% paraformaldehyde. Data was analyzed by curve fitting and non-linear regression (GraphPad Prism, GraphPad Software Inc., San Diego CA) to determine the percent neutralization at a given antibody concentration and the EC50. Antibody concentration was adjusted to consider the final 200 µl volume of the neutralization reaction in each well. For graphical representation raw data was “normalized” using GraphPad Prism (GraphPad Software Inc., San Diego CA) resulting in a sigmoidal dose response curve and infectivity data conversion to percent of maximal response (relative infection in percent).
Plaque reduction neutralization was performed as previously described(Graham et al., 1988). Briefly, HEp-2 cells were plated in 12 well plates in a monolayer and serial dilutions of serum were mixed with equal volumes of titered virus stock for 1 hour at 37°C. The serum dilution producing a 50% plaque reduction was calculated.
The assay was optimized for consistency and sensitivity. Parameters assessed included cell culture, viral titer and infection duration. Sub confluent HEp-2 cells with a passage number between 1 and 20 were determined to be the optimal cell type. The optimized condition included a cell count of 5×104 per well in a 96 well culture plate, which was freshly seeded, with a control well viral infection rate of 6–12%. As the virus replication cycle and cell growth cycle affect virus infection rates, the virus infection duration is important for accuracy of results. The assay should be completed after one round of virus replication but before a secondary round of infection could potentially begin. Based on a series of time points assessed, the ideal duration of infection is 16–18 hours and this is consistent with previous studies using this construct which indicate easily detectable infectivity within 20 hours (Hallak et al., 2000).
The “percentage law ” states that the amount of virus neutralized by a given concentration of antibody is constant irrespective of the total quantity of virus present so long as antibody is present in excess above the amount of virus in the assay (Andrewes, 1933; Klasse and Sattentau, 2001) (Pierson et al., 2006). Assay compliance with the percentage law provides further reassurance that the assay result reflects antibody affinity and is not related to quantity of virus present. To ascertain whether the RSV flow cytometry neutralization assay follows the “percentage law”, three dilutions of recombinant GFP-RSV at a multiplicity of infection (MOI) ranging from 0.03 to 1.5 were evaluated with serial dilutions of palivizumab with reproducible results in multiple experiments and data from a representative experiment is further described in detail (Figure 1). The EC50 at an MOI of 1.5, 0.15 and 0.03 was 2660, 2369 and 2372, respectively (Figure 1). The neutralization titer of palivizumab was not altered by different MOIs in the assessment of variables. Even at low virus dilutions, the EC50 of palivizumab is consistent when other variables like cell viability and age are fully controlled. While the assay follows the percentage law, it is noted that a set of conditions related to incubation time, cell number per well, and quality or infectivity of virus stock should be well controlled in this assay. For example, at low viral infectivity rates down to 6%, the EC50 of the positive control monoclonal antibody remains constant, but at viral infection rates <5% the measurement becomes unreliable. Low infection rates when using a relatively high MOI are typically caused by unhealthy cells that are at high passage number or overly confluent, or virus stock that is degraded. Therefore, to ensure consistency, we recommend control well infection rates in this assay to range from 6–12%.
Figure 1
Figure 1
Demonstration of reproducible neutralization of RSV-GFP by anti-RSV monoclonal antibody Palivizumab (Synagis®). EC50 of Palivizumab with 95% confidence intervals under three different MOI. Sigmoidal curves of antibody dilution (x-axis) versus (more ...)
Three further experiments were preformed in duplicate to assess neutralization by mouse serum, rabbit serum and human plasma against RSV, at a range of MOI (Figure 2). EC50 of mouse serum, rabbit serum and human plasma from a representative experiment are shown to be consistent despite altered experimental conditions (Figure 2).
Figure 2
Figure 2
Consistent neutralization (EC50) of human plasma, mouse serum, and rabbit serum under 4 different MOI (with 95% confidence intervals). Sigmoidal curves of antibody dilution (x-axis) versus GFP-RSV infected cells shown as neutralization curves at MOI of (more ...)
This flow cytometry neutralization assay has been used to assess RSV neutralizing antibody measurement in our laboratory and experimental results are consistent. Palivizumab from the same lot is used as the positive control in all experiments. To understand the degree of consistency, the EC50 of palivizumab from 33 experiments during a one-year period (Figure 3) were compared. Among 33 experiments, 20 were performed by operator 1 and the mean EC50 of palivizumab at a concentration of 1000 µg/ml was 1733±515.7 (mean±SD), 13 were performed by operator 2 with a mean EC50 of 1578±330.1 (mean±SD) (Figure 3).
Figure 3
Figure 3
Reproducibility of RSV flow cytometry neutralization assay. Figure 3a. Correlation of neutralization antibody titer (logEC50) by linear regression analysis of 16 mouse serum samples tested twice (on different dates) by operator 1. Figure 3b. Correlation (more ...)
The reproducibility of the neutralization assay was further evaluated. A comparison of the intraoperator reproducibility was made. The neutralization titers (logEC50) of 16 murine serum samples were assessed by one operator, twice, in two separate experiments and the linear regression analysis shows significant correlation, R2 = 0.9898, P < 0.0001 (95% CI of slope is 0.9479–1.065) (Figure 3a). Next, the interoperator reproducibility was tested. Of the 16 samples tested by operator 1, 10 samples (those with sufficient volume) were available for repeat assessment by operator 2. Additionally, another 6 samples that were previously tested by operator 1 in a separate experiment were added in the interoperator comparison experiment. The linear regression analysis demonstrates that the neutralization titer (logEC50) between two operators correlates significantly, R2 =0.9789, P< 0.0001 (95% CI of slope is 0.9934–1.176) (Figure 3b). A Spearman’s correlation assay also demonstrates correlation of the neutralization titer (logEC50) with an intraoperator correlation of r=0.9690, p<0.0001 (95% CI is 0.9080–0.9898) and an interoperator correlation r=0.9669, p<0.0001 (95% CI is 0.9019–0.9891).
A comparison of traditional PRNT to the flow-cytometry based neutralizing antibody assay was made by assessing serum from 68 cotton rats (Figure 4). The titers ranged from EC50 10- 3000 and a Spearman’s correlation analysis shows significant correlation between the PRNT and flow cytometry based neutralization assays (r = 0.9117, 95% CI is 0.8584–0.9456 and p < 0.0001).
Figure 4
Figure 4
Comparison of plaque reduction neutralization test and flow cytometry neutralization assay. 68 cotton rat serum samples were tested by plaque reduction neutralization test and flow cytometry neutralization. The linear regression analysis demonstrate significant (more ...)
Flow cytometry-based measurement of neutralizing activity for RSV is reliable and reproducible when the analysis is preformed under the optimized conditions defined here. Data derived from assessment of monoclonal antibody (palivizumab), human plasma, mouse serum and rabbit serum indicate that when performed in optimal conditions as described, the RSV flow cytometry based neutralization assay is reproducible, quantitative, and follows the “percentage law”.
The flow cytometry-based neutralization assay is a more efficient method than PRNT to evaluate RSV-specific humoral responses as it takes two days to complete (instead of 4 or 5) and up to 50 samples may easily be assessed in one experiment by a single operator. Additionally, the analysis of flow cytometry data is more efficient than manually counting plaques. The assay requires accurate cell counts and careful quality control of virus stock to ensure infectivity of the input virus. An infection rate of ≤ 5% in the negative control (no antibody) invalidates the assay results and suggests a problem with the quality of the cell substrate or virus stock. Therefore, we have identified 2 criteria which should be met as a measure of quality control, the infection rate in the negative control should be >5% and the EC50 of the 1000 µg/ml palivizumab positive control should ideally be within one standard deviation of the mean as established in a given laboratory setting for a given lot of antibody. The consistent EC50 results regardless of viral titer or infection rate indicates that the assay follows the percentage law and indicates that the assay result is a reflection of antibody neutralization and antibody affinity. To allow for this assay to be used more broadly, additional reporter viruses based on other strains of RSV, including a strain from subtype B, could be produced and assessed in a similar manner.
Assay optimization is helpful for research purposes, but for clinical product development, accurate, high-throughput assays are critical. Detection of neutralizing antibody in vaccine pre-clinical and clinical trials has historically been done utilizing the PRNT method. In recent years, viral immunologists have developed accurate, high throughput and reproducible neutralizing antibody assays, most notably in the flavivirus field (Pierson et al., 2006; Martin et al., 2007). Similar in method to the RSV assay described here, neutralizing antibody assays utilizing luciferase or GFP-expressing pseudovirus reporter systems have become more common and better standardized as new areas of viral research adopt this newer technology(Pierson et al., 2006; Sashihara et al., 2009).
Acknowledgements
The authors thank Dr. John Mascola for critical editing and advice and Dr. Theodore Pierson for expert opinion and education regarding neutralization and the importance of considering the Law of Mass Action in assay development.
Footnotes
This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.
  • Anderson LJ, Hierholzer JC, Bingham PG, Stone YO. Microneutralization test for respiratory syncytial virus based on an enzyme immunoassay. J Clin Microbiol. 1985;22:1050–1052. [PMC free article] [PubMed]
  • Andrewes CH, Elford WJ. Observations on anti-phage sera: I. 'The percentage law'. British Journal Experimental Pathology. 1933;14:367–376.
  • Collins PL, Graham BS. Viral and host factors in human respiratory syncytial virus pathogenesis. J Virol. 2008;82:2040–2055. [PMC free article] [PubMed]
  • Glezen WP, Paredes A, Allison JE, Taber LH, Frank AL. Risk of respiratory syncytial virus infection for infants from low-income families in relationship to age, sex, ethnic group, and maternal antibody level. J Pediatr. 1981;98:708–715. [PubMed]
  • Graham BS, Perkins MD, Wright PF, Karzon DT. Primary respiratory syncytial virus infection in mice. J Med Virol. 1988;26:153–162. [PubMed]
  • Hallak LK, Collins PL, Knudson W, Peeples ME. Iduronic acid-containing glycosaminoglycans on target cells are required for efficient respiratory syncytial virus infection. Virology. 2000;271:264–275. [PubMed]
  • Johnson S, Oliver C, Prince GA, Hemming VG, Pfarr DS, Wang SC, Dormitzer M, O'Grady J, Koenig S, Tamura JK, Woods R, Bansal G, Couchenour D, Tsao E, Hall WC, Young JF. Development of a humanized monoclonal antibody (MEDI-493) with potent in vitro and in vivo activity against respiratory syncytial virus. J Infect Dis. 1997;176:1215–1224. [PubMed]
  • Klasse PJ, Sattentau QJ. Mechanisms of virus neutralization by antibody. Curr Top Microbiol Immunol. 2001;260:87–108. [PubMed]
  • Martin JE, Louder MK, Holman LA, Gordon IJ, Enama ME, Larkin BD, Andrews CA, Vogel L, Koup RA, Roederer M, Bailer RT, Gomez PL, Nason M, Mascola JR, Nabel GJ, Graham BS. A SARS DNA vaccine induces neutralizing antibody and cellular immune responses in healthy adults in a Phase I clinical trial. Vaccine. 2008;26:6338–6343. [PMC free article] [PubMed]
  • Martin JE, Pierson TC, Hubka S, Rucker S, Gordon IJ, Enama ME, Andrews CA, Xu Q, Davis BS, Nason M, Fay M, Koup RA, Roederer M, Bailer RT, Gomez PL, Mascola JR, Chang GJ, Nabel GJ, Graham BS. A West Nile virus DNA vaccine induces neutralizing antibody in healthy adults during a phase 1 clinical trial. J Infect Dis. 2007;196:1732–1740. [PMC free article] [PubMed]
  • Mascola JR, Louder MK, Winter C, Prabhakara R, De Rosa SC, Douek DC, Hill BJ, Gabuzda D, Roederer M. Human immunodeficiency virus type 1 neutralization measured by flow cytometric quantitation of single-round infection of primary human T cells. J Virol. 2002;76:4810–4821. [PMC free article] [PubMed]
  • Pierson TC, Sanchez MD, Puffer BA, Ahmed AA, Geiss BJ, Valentine LE, Altamura LA, Diamond MS, Doms RW. A rapid and quantitative assay for measuring antibody-mediated neutralization of West Nile virus infection. Virology. 2006;346:53–65. [PubMed]
  • Sashihara J, Burbelo PD, Savoldo B, Pierson TC, Cohen JI. Human antibody titers to Epstein-Barr Virus (EBV) gp350 correlate with neutralization of infectivity better than antibody titers to EBV gp42 using a rapid flow cytometry-based EBV neutralization assay. Virology. 2009;391:249–256. [PMC free article] [PubMed]